Brief Summary
The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.
Approved for marketing
Hemoglobinuria, Paroxysmal
Drug: eculizumab
600mg IV every week and 900mg IV every 2 weeks
Eligibility Criteria
Inclusion Criteria:
- PNH;
- At least 18 years old
- Avoid conception; and
- Willing and able to give written informed consent
Exclusion Criteria:
- Active bacterial infection
- Participation in any other drug trial
- Pregnant breast feeding, or intending to conceive
- Not vaccinated against N meningitidis
Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations
Anthony Botti
Livingston, New Jersey, United States
Alexion Pharmaceuticals, Inc.
NCT Number
MeSH Terms
Hemoglobinuria
Hemoglobinuria, Paroxysmal
Eculizumab